JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) but lowered the price target from $19 to $18.

March 27, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on ORIC Pharmaceuticals but has lowered the price target from $19 to $18.
While the reduction in price target might suggest a slight adjustment in valuation expectations, the maintenance of an Overweight rating indicates a continued positive outlook on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the reaffirmed confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100